Maria-Jose Ribal

6PUBLICATIONS
38CO-AUTHORS
Medical biotechnology diagnostics (incl. biosensors)BiomechanicsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 28, 2026
Correction: Pérez et al. Biomarker-Based Nomogram to Predict Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer. Biomedicines 2025, 13, 740.

|Jul 21, 2026
Exercise and Physical Activity as Modifiable Risk Factors for Benign Prostatic Hyperplasia: An Update.

|Mar 28, 2025
Biomarker-Based Nomogram to Predict Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer.

Meritxell Pérez, Juan José Lozano, Mercedes Ingelmo-Torres

|Dec 18, 2024
cfDNA fragmentation patterns correlate with tumor burden measured via PSMA PET/CT volumetric parameters in patients with biochemical recurrence of prostate cancer.

Gary Amseian, Marcel Figueras, Joel Mases

|Sep 26, 2024
Influences on androgen deprivation therapy prescribing before surgery in high-risk prostate cancer.

Jennifer Dunsmore, Eilidh Duncan, Sara J MacLennan

|May 24, 2023
Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis.

Joan Carles, Rafael A Medina-Lopez, Javier Puente

Pageof 1

Frequent Collaborators

2 joint publications

Antoni Vilaseca

2 joint publications

Begoña Mellado

2 joint publications

Antonio Coy

2 joint publications

Antoine G van der Heijden